Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Markus Pfirrmann"'
Autor:
Rainer Krahl, Thoralf Lange, Dietger Niederwieser, Christian Niederwieser, Ulrich von Grünhagen, Volker Lakner, Markus Pfirrmann, Kathleen Jentsch-Ullrich, Claudia Spohn, Michael Cross, Haifa Kathrin Al-Ali, Arthur Gil, Rüdiger Hehlmann, Christian Junghanss, Michael Assmann, Michael W. Deininger
Publikováno v:
Leukemia & Lymphoma. 61:2821-2830
The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML).AfterAdditive specific inhibition of CML cells by IM/HU was detectedIM/HU combination was more potent in selectively inhibiting
Autor:
Marie von Lilienfeld-Toal, Mathias Hänel, Kirsi Manz, Beate Krammer-Steiner, Thomas Illmer, Markus Pfirrmann, Christian Fabisch, Annamaria Brioli, Andreas Schwarzer, Andreas Hochhaus, Lars-Olof Mügge, Gabriele Prange-Krex, Stefan Knop
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:749-759
The German Maintenance Study (GERMAIN) was designed to evaluate the impact of lenalidomide maintenance after induction therapy with bortezomib, melphalan and prednisolone (VMP) in transplant-ineligible newly diagnosed multiple myeloma (MM) patients.
Autor:
Hubert Serve, Mathias Haenel, Johanna Tischer, Martin Bornhaeuser, Christoph Schliemann, Karsten Spiekermann, Kerstin Schaefer-Eckart, Wolfgang E. Berdel, Lutz P. Mueller, Gesine Bug, Stefan Klein, Georg Lenz, Christoph Schmid, Dietrich W. Beelen, Edgar Jost, Nael Alakel, Markus Pfirrmann, Gerhard Ehninger, Matthias Stelljes, Wolf Roesler, Friedrich Stoelzel, Michael Kramer, Uwe Platzbecker, Christoph Röllig, Johannes Schetelig, Bertram Glass, Andreas Burchert
Allogeneic hematopoietic cell transplantation (HCT) offers the highest chance for cure in patients with adverse-risk acute myeloid leukemia (AML) when performed in first remission (CR1). In contrast, patients in CR1 with favorable risk do not seem to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56fc06634c9e3a329a614560de2b95ec
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/98269
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/98269
Autor:
Matthew D Snape, Melanie Gündert, Anette-Gabriele Ziegler, Peter Achenbach, Reinhard Berner, Kristina Casteels, Thomas Danne, Joerg Hasford, Olga Kordonouri, Karin Lange, Helena Elding Larsson, Markus Lundgren, Agnieszka Szypowska, John A Todd, Ezio Bonifacio, Nicole Zubizarreta, Christiane Winkler, Åke Lernmark, Daniel Agardh, Cigdem Gezginci, Claudia Ramminger, Marlon Scholz, Katharina Warncke, Carin Andrén Aronsson, Rasmus Bennet, Lina Fransson, Zeliha Mestan, Caroline Nilsson, Anita Ramelius, Carina Törn, Sarah Hogg, Catherine Owen, Lidia Groele, Florian Haupt, Claudia Matzke, Robin Assfalg, Matthew Snape, Felix Reschke, Marcin L Pekalski, Andreas Weiss, Andrew Johnston, Manja Jolink, Loredana Marcovecchio, Mariusz Ołtarzewski, Stefanie Arnolds, Annika Kölln, Markus Pfirrmann, Corinna Barz, Karina Blasius, Nadine Friedl, Adriano Gomez-Bantel, Martin Heigermoser, Bianca Höfelschweiger, Nadine Klein, Ramona Lickert, Rebecca Niewöhner, Katharina Schütte-Borkovec, Mira Taulien, Lara Vogel, Franziska Voß, José Maria Zapardiel Gonzalo, Philipp Sifft, Heidi Kapfelsberger, Merve Vurucu, Katharina Sarcletti, Stefanie Jacobson, Yulia Grinin, John A. Todd, Anette-G. Ziegler, Marcin L. Pekalski, Anette G. Ziegler, Annre Rochtus, An Jacobs, Jasmin Paulus, Brontë Vrancken, Natalie Van den Driessche, Renka Van Heyste, Janne Houben, Veerle Vanhuyse, Sevina Dietz, Gita Gemulla, Manja Gottschalk-Schwarz, Sophie Heinke, Angela Hommel, Susann Kowal, Fabian Lander, Robert Morgenstern, Marc Weigelt, Sari Arabi, Raphael Hoffmann, Ruth Blechschmidt, Franziska Ehrlich, Anja Loff, Laura Galuschka, Ute Holtkamp, Nils Janzen, Sarah Landsberg, Erika Marquardt, Frank Roloff, Kerstin Semler, Thekla von dem Berge, Melanie Bunk, Simone Färber-Meisterjahn, Willi Grätz, Ines Greif, Melanie Herbst, Anna Hofelich, Benjamin Marcus, Annette Munzinger, Jasmin Ohli, Franziska Reinmüller, Tiziana Welzhofer, Sylwia Dybkowska, Katarzyna Dżygało, Dorota Owczarek, Katarzyna Popko, Agnieszka Skrobot, Anna Taczanowska, Beata Zduńczyk, Charlotte Brundin, Ida Jönsson, Sara Maroufkhani, Evelyn Tekum Amboh, Katarzyna Gajewska-Knapik, Elena Romero, Suzannah Twiss, Helen Gallon, Laura Gebbie, Fiona Jenkinson, Steven Pratt, Steve Robson, Claire Simmister, Evelyn Thomson, Eileen Walton
Publikováno v:
BMJ Open, Vol 11, Iss 11 (2021)
BMJ Open
BMJ Open 11:e052449 (2021)
BMJ Open
BMJ Open 11:e052449 (2021)
IntroductionThe Global Platform for the Prevention of Autoimmune Diabetes-SINT1A Study is designed as a randomised, placebo-controlled, double-blind, multicentre, multinational, primary prevention study aiming to assess whether daily administration o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::307df38401cb50d305c4eda84bd4c727
https://mediatum.ub.tum.de/doc/1653368/document.pdf
https://mediatum.ub.tum.de/doc/1653368/document.pdf
Autor:
Andrija Bogdanovic, Boris Labar, Martin Höglund, Edgar Faber, Hele Everaus, Richard E. Clark, Adriana Colita, Rüdiger Hehlmann, Sonja Heibl, Anna G. Turkina, Ulla Olsson-Strömberg, Francisco Cervantes, Michele Baccarani, Tomasz Sacha, Verena S. Hoffmann, Michael Lauseker, Daniela Zackova, Markus Pfirrmann, Andreas Hochhaus, Laimonas Griskevicius, Perttu Koskenvesa, Susanne Saussele, Irena Preložnik Zupan, Joerg Hasford, Andrey Zaritskey, Gert J. Ossenkoppele, Fausto Castagnetti, Witold Prejzner, François Guilhot, Joelle Guilhot
Publikováno v:
Leukemia
Leukemia, 34(8), 2138-2149. Nature Publishing Group
Leukemia, London : Nature Publishing Group, 2020, vol. 34, no. 8, p. 2138-2149
Pfirrmann, M, Clark, R E, Prejzner, W, Lauseker, M, Baccarani, M, Saussele, S, Guilhot, F, Heibl, S, Hehlmann, R, Faber, E, Turkina, A, Ossenkoppele, G, Höglund, M, Zaritskey, A, Griskevicius, L, Olsson-Strömberg, U, Everaus, H, Koskenvesa, P, Labar, B, Sacha, T, Zackova, D, Cervantes, F, Colita, A, Zupan, I, Bogdanovic, A, Castagnetti, F, Guilhot, J, Hasford, J, Hochhaus, A & Hoffmann, V S 2020, ' The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia ', Leukemia, vol. 34, no. 8, pp. 2138-2149 . https://doi.org/10.1038/s41375-020-0931-9
Leukemia, 34(8), 2138-2149. Nature Publishing Group
Leukemia, London : Nature Publishing Group, 2020, vol. 34, no. 8, p. 2138-2149
Pfirrmann, M, Clark, R E, Prejzner, W, Lauseker, M, Baccarani, M, Saussele, S, Guilhot, F, Heibl, S, Hehlmann, R, Faber, E, Turkina, A, Ossenkoppele, G, Höglund, M, Zaritskey, A, Griskevicius, L, Olsson-Strömberg, U, Everaus, H, Koskenvesa, P, Labar, B, Sacha, T, Zackova, D, Cervantes, F, Colita, A, Zupan, I, Bogdanovic, A, Castagnetti, F, Guilhot, J, Hasford, J, Hochhaus, A & Hoffmann, V S 2020, ' The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia ', Leukemia, vol. 34, no. 8, pp. 2138-2149 . https://doi.org/10.1038/s41375-020-0931-9
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our aim wa
Autor:
Brigitte Schlegelberger, Alice Fabarius, Rüdiger Hehlmann, Dieter K. Hossfeld, Gabriela M. Baerlocher, Alois Gratwohl, Hans-Jochem Kolb, Astghik Voskanyan, Christoph Nerl, Susanne Saußele, Tim H. Brümmendorf, Sebastien Rinaldetti, Claudia Haferlach, Lida Kalmanti, Andreas Neubauer, Patrick Wuchter, Wolfgang Seifarth, Birgit Spieß, Markus Pfirrmann, Stefan W. Krause, Sakk, Michele Baccarani, Katharina Kohlbrenner, Andreas Burchert, Jörg Hasford, Michael Lauseker, Andreas Hochhaus
Publikováno v:
Leukemia
Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus; Kalmanti, Lida; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Haferlach, Claudia; Schlegelberger, Brigitte; Fabarius, Alice; Seifarth, Wolfgang; Spieß, Birgit; Wuchter, Patrick; Krause, Stefan; Kolb, Hans-Jochem; Neubauer, Andreas; Hossfeld, Dieter K; Nerl, Christoph; Gratwohl, Alois; Baerlocher, Gabriela M.; ... (2020). High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 34(8), pp. 2074-2086. Springer Nature 10.1038/s41375-020-0826-9
Leukemia, 34(8), 2074-2086. Nature Publishing Group
for the SAKK and the German CML Study Group 2020, ' High-risk additional chromosomal abnormalities at low blast counts herald death by CML ', Leukemia, vol. 34, no. 8, pp. 2074-2086 . https://doi.org/10.1038/s41375-020-0826-9
Hehlmann, Rüdiger; Voskanyan, Astghik; Lauseker, Michael; Pfirrmann, Markus; Kalmanti, Lida; Rinaldetti, Sebastien; Kohlbrenner, Katharina; Haferlach, Claudia; Schlegelberger, Brigitte; Fabarius, Alice; Seifarth, Wolfgang; Spieß, Birgit; Wuchter, Patrick; Krause, Stefan; Kolb, Hans-Jochem; Neubauer, Andreas; Hossfeld, Dieter K; Nerl, Christoph; Gratwohl, Alois; Baerlocher, Gabriela M.; ... (2020). High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia, 34(8), pp. 2074-2086. Springer Nature 10.1038/s41375-020-0826-9
Leukemia, 34(8), 2074-2086. Nature Publishing Group
for the SAKK and the German CML Study Group 2020, ' High-risk additional chromosomal abnormalities at low blast counts herald death by CML ', Leukemia, vol. 34, no. 8, pp. 2074-2086 . https://doi.org/10.1038/s41375-020-0826-9
Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One
Autor:
Philipp J. Jost, Gabriele Prange-Krex, Wolfgang Seifarth, Tim H. Brümmendorf, Martin Müller, Joelle Guilhot, Robert Eckert, Susanne Saussele, Christian Dietz, Cornelius F. Waller, Carsten Janβen, Birgit Spiess, Viktor Janzen, Gerd Büschel, Sebastien Rinaldetti, Philippe Schafhausen, Markus Pfirrmann, Stefan Hanzel, Martine Klausmann, Panayiotidis Panagiotidis, Jolanta Dengler, Kirsi Manz, Maria Elisabeth Goebeler, Maria Pagoni, Regina Herbst, Wolf-Karsten Hofmann, Thomas Illmer, Maria Dimou, Alice Fabarius, Alexander Kiani, Andreas Burchert, Francois-Xavier Mahon
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:266-271
Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox reg
Autor:
Martina Crysandt, Joachim R. Göthert, Susanne Saussele, Susanne Isfort, Markus Pfirrmann, Kirsi Manz, Alexander Kiani, Tim H. Brümmendorf, Denise Kohn, Uta Wolber, Thomas Illmer, Andreas Burchert, Lino L. Teichmann, Mareille Warnken-Uhlich, Dominik Wolf, Philippe Schafhausen, Andreas Hochhaus
Publikováno v:
Blood. 138:3608-3608
Introduction: The licenced starting dose of bosutinib is 400 mg QD for first line therapy and 500 mg QD in later lines in CML. Gastrointestinal (GI) adverse events (AE) are observed in up to 90% in similar patient cohorts (BYOND, Hochhaus et al; Leuk
Autor:
Stephan Kremers, Michael Lauseker, Walter Lindemann, Doris Kraemer, Susanne Saussele, Joerg Hasford, Rüdiger Hehlmann, Markus Pfirrmann
Publikováno v:
Cancer. 123:2467-2471
BACKGROUND Smoking is suspected to not only be a risk factor for chronic myeloid leukemia but an adverse prognostic factor for the disease as well. The objective of the current study was to investigate the impact of smoking on survival and progressio
Autor:
Michele Baccarani, Joerg Hasford, Anna G. Turkina, Michael Lauseker, Elza Lomaia, Laimonas Griskevicius, Joelle Guilhot, Verena S. Hoffmann, Andreas Hochhaus, Gert J. Ossenkoppele, Perttu Koskenvesa, Daniela Zackova, Markus Pfirrmann, Sonja Heibl, Ulla Olsson-Strömberg, Andrija Bogdanovic, Edgar Faber, Gabriele Schubert-Fritschle, Richard E. Clark, Witold Prejzner, Katharina Bachl, Tomasz Sacha
Publikováno v:
American journal of hematology, Hoboken : Wiley, 2019, vol. 94, no. 11, p. 1236-1243
Lauseker, M, Bachl, K, Turkina, A, Faber, E, Prejzner, W, Olsson-Strömberg, U, Baccarani, M, Lomaia, E, Zackova, D, Ossenkoppele, G, Griskevicius, L, Schubert-Fritschle, G, Sacha, T, Heibl, S, Koskenvesa, P, Bogdanovic, A, Clark, R E, Guilhot, J, Hoffmann, V S, Hasford, J, Hochhaus, A & Pfirrmann, M 2019, ' Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin ', American Journal of Hematology, vol. 94, no. 11, pp. 1236-1243 . https://doi.org/10.1002/ajh.25628
American Journal of Hematology, 94(11), 1236-1243. Wiley-Liss Inc.
Lauseker, M, Bachl, K, Turkina, A, Faber, E, Prejzner, W, Olsson-Strömberg, U, Baccarani, M, Lomaia, E, Zackova, D, Ossenkoppele, G, Griskevicius, L, Schubert-Fritschle, G, Sacha, T, Heibl, S, Koskenvesa, P, Bogdanovic, A, Clark, R E, Guilhot, J, Hoffmann, V S, Hasford, J, Hochhaus, A & Pfirrmann, M 2019, ' Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin ', American Journal of Hematology, vol. 94, no. 11, pp. 1236-1243 . https://doi.org/10.1002/ajh.25628
American Journal of Hematology, 94(11), 1236-1243. Wiley-Liss Inc.
Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known on the prognosis of these patients. Our aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11c38168c7c11aa1857d62411c051b5c
https://ruj.uj.edu.pl/xmlui/handle/item/256062
https://ruj.uj.edu.pl/xmlui/handle/item/256062